Topic: CAR-T

Allogene biotech investments

5. Allogene Therapeutics

Allogene started life with a suite of ready-made candidates—along with a whopping $300 million series A round and former Kite Pharma executives Arie Belldegrun and David Chang as co-founders.

A CAR-T approach to lupus

University of Tennessee scientists have designed a CD19-targeting CAR-T for lupus and have shown encouraging results in a mouse study.